Emerging Role of Fibroblast Growth Factors 15/19 and 21 as Metabolic Integrators in the Liver

被引：98

作者：

Cicione, Claudia ^{[1
]}

Degirolamo, Chiara ^{[1
]}

Moschetta, Antonio ^{[1
,2
,3
]}

机构：

[1] Consorzio Mario Negri Sud, Dept Translat Pharmacol, Lab Lipid Metab & Canc, Santa Maria Imbaro, CH, Italy

[2] Univ Bari, Clin Med A Murri, Dept Internal & Publ Med, I-66030 Chieti, Italy

[3] Natl Canc Inst Giovanni Paolo II, Bari, Italy

来源：

HEPATOLOGY | 2012年 / 56卷 / 06期

关键词：

ACTIVATED-RECEPTOR-GAMMA; BILE-ACID SYNTHESIS; BETA-KLOTHO; PPAR-ALPHA; HEPATOCELLULAR-CARCINOMA; CIRCADIAN-RHYTHM; TRANSGENIC MICE; MOUSE MODEL; EXPRESSION; FGF21;

D O I：

10.1002/hep.25929

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Fibroblast growth factors (FGFs) 15/19 and 21 belong to the FGF endocrine subfamily. They present the intriguing characteristic to be transcribed and secreted in certain tissues and to act as hormones. The insulin-mimetic properties of FGF21 and the regulatory role of FGF15/19 in bile acid and glucose homeostasis endorse these hormones as druggable targets in metabolic disorders. Here, we present details on discoveries, identification, transcriptional regulation, and mechanism of actions of FGF15/19 and FGF21 with a critical perspective view on their putative role as metabolic integrators in the liver. (HEPATOLOGY 2012;56:2404-2411)

引用

页码：2404 / 2411

页数：8

共 69 条

[1] Plasma FGF21 displays a circadian rhythm during a 72-h fast in healthy female volunteers [J].

Andersen, Birgitte ;

Beck-Nielsen, Henning ;

Hojlund, Kurt .

CLINICAL ENDOCRINOLOGY, 2011, 75 (04) :514-519

[2]

Badman MK, 2007, CELL METAB, V5, P426, DOI 10.1016/j.cmet.2007.05.002

[3] Fibroblast Growth Factor 21-Deficient Mice Demonstrate Impaired Adaptation to Ketosis [J].

Badman, Michael K. ;

Koester, Anja ;

Flier, Jeffrey S. ;

Kharitonenkov, Alexei ;

Maratos-Flier, Eleftheria .

ENDOCRINOLOGY, 2009, 150 (11) :4931-4940

[4] The FGF family: biology, pathophysiology and therapy [J].

Beenken, Andrew ;

Mohammadi, Moosa .

NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (03) :235-253

[5] Fibroblast Growth Factor-19, a Novel Factor That Inhibits Hepatic Fatty Acid Synthesis [J].

Bhatnagar, Sushant ;

Damron, Holly A. ;

Hillgartner, F. Bradley .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (15) :10023-10033

[6] Identification of a hormonal basis for gallbladder filling [J].

Choi, Mihwa ;

Moschetta, Antonio ;

Bookout, Angie L. ;

Peng, Li ;

Umetani, Michihisa ;

Holmstrom, Sam R. ;

Suino-Powell, Kelly ;

Xu, H. Eric ;

Richardson, James A. ;

Gerard, Robert D. ;

Mangelsdorf, David J. ;

Kliewer, Steven A. .

NATURE MEDICINE, 2006, 12 (11) :1253-1255

[7] Circulating Fibroblast Growth Factor 21 Is Induced by Peroxisome Proliferator-Activated Receptor Agonists But Not Ketosis in Man [J].

Christodoulides, Constantinos ;

Dyson, Pamela ;

Sprecher, Dennis ;

Tsintzas, Kostas ;

Karpe, Fredrik .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (09) :3594-3601

[8] Fibroblast Growth Factor 21 Corrects Obesity in Mice [J].

Coskun, Tamer ;

Bina, Holly A. ;

Schneider, Michael A. ;

Dunbar, James D. ;

Hu, Charlie C. ;

Chen, Yanyun ;

Moller, David E. ;

Kharitonenkov, Alexei .

ENDOCRINOLOGY, 2008, 149 (12) :6018-6027

[9] Increased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease [J].

Dushay, Jody ;

Chui, Patricia C. ;

Gopalakrishnan, Gosala S. ;

Varela-Rey, Marta ;

Crawley, Meghan ;

Fisher, Ffolliott M. ;

Badman, Michael K. ;

Martinez-Chantar, Maria L. ;

Maratos-Flier, Eleftheria .

GASTROENTEROLOGY, 2010, 139 (02) :456-463

[10] Fibroblast Growth Factor-21 Regulates PPARγ Activity and the Antidiabetic Actions of Thiazolidinediones [J].

Dutchak, Paul A. ;

Katafuchi, Takeshi ;

Bookout, Angie L. ;

Choi, Jang Hyun ;

Yu, Ruth T. ;

Mangelsdorf, David J. ;

Kliewer, Steven A. .

CELL, 2012, 148 (03) :556-567

← 1 2 3 4 5 6 7 →